DPP4 and type 2 diabetes mellitus: A novel class of oral antidiabetic agents, the dipeptidyl peptidase-IV (DPP-IV) inhibitors (or gliptins), such as sitagliptin, has increasingly gained emphasis in the therapeutic managing of T2DM patients by potentiating the action of incretins [20, 21].